Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 2, 2023

Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia

GlobeNewswire February 14, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verve Therapeutics, Inc. - VERV

Newsfile January 7, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

PR Newswire January 4, 2023

Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

Newsfile December 30, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

PR Newswire December 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

PR Newswire December 19, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verve Therapeutics, Inc. - VERV

Newsfile December 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

PR Newswire December 12, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

PR Newswire December 5, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

Newsfile November 30, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

PR Newswire November 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verve Therapeutics, Inc. - VERV

Newsfile November 19, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

PR Newswire November 14, 2022

Verve Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

Newsfile November 9, 2022

Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 7, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc. - VERV

Newsfile November 1, 2022

Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting

GlobeNewswire October 31, 2022